← Back to headlines
H.C. Wainwright Reiterates Buy Rating on Legend Biotech
Investment bank H.C. Wainwright has maintained its buy rating on Legend Biotech stock, citing continued confidence in the company's clinical pipeline and commercial prospects.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
